Cerevel Therapeutics Holdings, Inc. (CERE)
NASDAQ: CERE · IEX Real-Time Price · USD
42.26
-0.26 (-0.61%)
At close: May 7, 2024, 4:00 PM
42.37
+0.11 (0.25%)
After-hours: May 7, 2024, 4:10 PM EDT
CERE Employees
Cerevel Therapeutics Holdings had 334 employees on December 31, 2023. The number of employees increased by 36 or 12.08% compared to the previous year.
Employees
334
Change (1Y)
36
Growth (1Y)
12.08%
Revenue / Employee
n/a
Profits / Employee
-$1,295,934
Market Cap
7.69B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 334 | 36 | 12.08% |
Dec 31, 2022 | 298 | 98 | 49.00% |
Dec 31, 2021 | 200 | 96 | 92.31% |
Dec 31, 2020 | 104 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Bio-Rad Laboratories | 8,030 |
Bio-Rad Laboratories | 8,030 |
Stevanato Group | 5,634 |
Globus Medical | 5,000 |
Penumbra | 4,200 |
Masimo | 3,800 |
Jazz Pharmaceuticals | 2,800 |
Inspire Medical Systems | 1,011 |
CERE News
- 19 days ago - Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study - Reuters
- 19 days ago - Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease - GlobeNewsWire
- 4 months ago - CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders - Business Wire
- 4 months ago - Cramer names biopharma companies to watch as industry mergers start to pile up - CNBC
- 5 months ago - CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE - Business Wire
- 5 months ago - AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio - Investopedia
- 5 months ago - AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say - Reuters
- 5 months ago - Cramer reacts to AbbVie buying Cerevel Therapeutics - Invezz